- Home
- MDXG
MDXG
MiMedx Group Inc
as 04-18-2025 12:39pm EST
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | MARIETTA |
| Market Cap: | 1.2B | IPO Year: | N/A |
| Target Price: | $12.00 | AVG Volume (30 days): | 587.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.28 | EPS Growth: | -22.18 |
| 52 Week Low/High: | $5.47 - $10.14 | Next Earning Date: | 04-30-2025 |
| Revenue: | $348,879,000 | Revenue Growth: | 8.52% |
| Revenue Growth (this year): | 10.04% | Revenue Growth (next year): | 11.53% |
Stock Insider Trading Activity of MiMedx Group Inc (MDXG)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Maersk-Moller Kimberly | MDXG | Chief Commercial Officer | Mar 17 '25 | Sell | $8.04 | 1,759 | $14,142.36 | 309,077 | |
| Hulse William Frank IV | MDXG | General Counsel and CAO | Mar 13 '25 | Sell | $7.89 | 54,596 | $430,762.44 | 460,544 | |
| Maersk-Moller Kimberly | MDXG | Chief Commercial Officer | Mar 13 '25 | Sell | $7.89 | 4,106 | $32,396.34 | 309,077 | |
| Hulse William Frank IV | MDXG | General Counsel and CAO | Mar 10 '25 | Sell | $7.80 | 81,446 | $635,278.80 | 460,544 | |
| Maersk-Moller Kimberly | MDXG | Chief Commercial Officer | Feb 28 '25 | Sell | $8.41 | 2,111 | $17,742.95 | 309,077 | |
| Whitlow Ricci S | MDXG | Chief Operating Officer | Feb 13 '25 | Sell | $8.28 | 61,420 | $508,557.60 | 403,019 |
Latest MiMedx Group Inc News
MDXG Breaking Stock News: Dive into MDXG Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
MIMEDX to Host First Quarter 2025 Operating and Financial Results Conference Call on April 30
GlobeNewswire
9 days ago
MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences
Simply Wall St.
a month ago
MiMedx Group, Inc.'s (NASDAQ:MDXG) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Zacks
a month ago
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength?
MT Newswires
a month ago
Mimedx Group Insider Sold Shares Worth $430,762, According to a Recent SEC Filing
Thomson Reuters StreetEvents
2 months ago
Q4 2024 MiMedx Group Inc Earnings Call
GlobeNewswire
2 months ago
MIMEDX to Present at TD Cowen 45th Annual Health Care Conference
GuruFocus.com
2 months ago
MiMedx Group Inc (MDXG) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Compare MDXG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MDXG MiMedx Group Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.